80P A phase Ib/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer

March 17, 2026ESMO OpenOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research examines the effectiveness of cadonilimab combined with chemotherapy compared to placebo in patients with advanced lung cancer who have experienced checkpoint inhibitors.
Conducted exploratory analyses using the EORTC QLQ-C30 and QLQ-LC13 questionnaires.
Analyzed time to clinically meaningful deterioration using a Cox proportional hazards model.
Performed mixed-model analyses for overall change from baseline scores between treatment arms.
In patients under 65, cadonilimab plus chemotherapy significantly delayed deterioration in multiple quality of life dimensions.
In patients over 65, similar benefits were observed, particularly in pain and alopecia scores.
No benefits were noted for the placebo group in either age subgroup.

Post hoc analyses show cadonilimab plus chemotherapy benefits overall change and TTD in advanced lung cancer patients, suggesting improved outcomes.

No takes yet. Share an insight, caveat, or question.

Han et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share